Day One Biopharmaceuticals (DAWN) has provided an announcement.
Day One Biopharmaceuticals, Inc. has struck a deal with MabCare Therapeutics, obtaining exclusive rights to develop, produce, and sell the innovative cancer drug MTX-13 (now DAY301) everywhere except Greater China. Day One will pay MabCare $55 million upfront, with potential future payments totaling $1.15 billion based on development success and sales, along with royalties. The agreement, which includes standard clauses for termination and patent dispute resolution, will be detailed in Day One’s upcoming quarterly report. The company has also issued a press release and updated its corporate presentation to reflect this significant licensing agreement.
For detailed information about DAWN stock, go to TipRanks’ Stock Analysis page.
